Braftovi (encorafenib capsules − Array) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has BRAF V600E mutation-positive disease
• Patient has advanced or metastatic disease
• The medication will be used in combination with Erbitux (cetuximab intravenous infusion) or Vectibix (panitumumab intravenous infusion)

Approval duration

1 year